Can kisqali be taken with hormone therapy for breast cancer?

Can Kisqali be combined with hormone therapy?

Kisqali is approved to be used together with an aromatase inhibitor or fulvestrant as first-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. This combination is the standard approach in both clinical trials and daily practice. The drug blocks CDK4/6 proteins, slowing cancer cell growth, while hormone therapy reduces estrogen-driven growth.

How does this combination affect side effects?

Patients taking Kisqali plus hormone therapy often see increased risk of low white blood cell counts, liver enzyme changes, and QT interval prolongation on ECG. Monitoring blood counts and liver function every two weeks for the first two cycles, then monthly, is required. ECG is performed at baseline and every two weeks for the first two cycles as well.

What happens if someone stops hormone therapy?

Stopping the hormone therapy component may reduce overall progression-free survival. Clinical data show that monotherapy with Kisqali is nicht empfohlen for this patient group. The company does not recommend using Kisqali alone in hormone receptor-positive breast cancer.

How long does this treatment continue?

Treatment continues indefinitely until disease progression or unacceptable toxicity. Patients typically take 600 mg Kisqali (three 200 mg tablets) once daily for 21 days followed by 7 days off, aligned with the continuous daily dosing of the hormone therapy partner.

When does the Kisqali patent expire?

The compound patent covering ribociclib expires in 2031 in the US. The composition-of-matter patent expires in 2035. The drug manufacturer Novartis has active litigation against proposed biosimilar entrants. DrugPatentWatch.com lists several extension applications and method-of-use patents that may further delay generic entry.